Experimental combo for blood cancer shows early promise but study halted
NCT ID NCT03837509
First seen Nov 04, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tested whether adding an experimental drug (INCB001158) to a standard therapy (daratumumab) could help people with multiple myeloma that had returned or stopped responding to treatment. The trial was open to adults who had already tried at least three prior treatments. The study was terminated early, so results are limited, but the goal was to compare safety and tumor response between the combination and daratumumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Oncology Associates (Wilmot)
Tucson, Arizona, 85711, United States
-
Charite - Universit�Tsmedizin Berlin
Berlin, 13353, Germany
-
Clinica Universidad de Navarra (Cun)
Pamplona, 31008, Spain
-
Comprehensive Cancer Centers of Nevada - Twain
Las Vegas, Nevada, 89169, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fundacion Jimenez Diaz University Hospital
Madrid, 28040, Spain
-
Hospital Clinic I Provincial
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital General Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Doctor Peset
Valencia, 46017, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Y Politcnico de La Fe
Valencia, 46026, Spain
-
Ico Institut Catala D Oncologia
Barcelona, 08908, Spain
-
Lineberger Comprehensive Cancer Center At University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
New York Oncology Hematology
Albany, New York, 12206, United States
-
Oncology Hematology Care, Inc
Cincinnati, Ohio, 45236, United States
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Southern Cancer Center
Daphne, Alabama, 36526, United States
-
Texas Oncology - Fort Worth South Henderson
Fort Worth, Texas, 76104, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
Texas Oncology San Antonio
San Antonio, Texas, 78240, United States
-
Texas Oncology-Austin Midtown
Austin, Texas, 78705, United States
-
Universitatsklinikum Munster
Münster, 48149, Germany
-
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, 55131, Germany
-
University of Heidelberg
Heidelberg, 69117, Germany
-
University of Virginia
Charlottesville, Virginia, 22903, United States
-
Virginia Cancer Specialists-Fairfax
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.